1
|
See YP, Htay H, Teixeira-Pinto A, Pascoe EM, Hawley C, Cho Y, Zhao E, Johnson DW. Utility of serum beta-trace protein as a tool for estimating residual kidney function in peritoneal dialysis patients. Perit Dial Int 2020; 41:226-235. [PMID: 32815791 DOI: 10.1177/0896860820945464] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Beta-trace protein (BTP) is a novel marker for residual kidney function (RKF) without need for urinary collection. We aimed to examine its utility as a tool for estimating RKF in incident peritoneal dialysis (PD) patients. METHODS This was a post hoc analysis of incident PD patients from the balANZ trial cohort. The outcomes evaluated were trends of serum BTP concentration with time, factors associated with change in BTP using mixed-effect multilevel linear regression and correlation of BTP with mean urinary urea and creatinine clearances (measured glomerular filtration rate (GFR)). Performances of two BTP-derived equations (Shafi-Eqn and Steubl-Eqn) to estimate GFR were evaluated by reporting bias (median difference between estimated and measured GFR), precision (interquartile range of median bias), accuracy (±2 mL/min of measured GFR) and P30 (percentage estimates within 30% of measured GFR) with confidence intervals (CIs) generated by bootstrapping 2000 replicates. The agreement between BTP-estimated GFR and measured GFR was also plotted graphically on Bland-Altman analysis. RESULTS The study included 161 PD patients. BTP concentration increased with dialysis vintage and was inversely correlated with measured GFR (r = -0.64). Larger increases in BTP were associated with longer PD vintage and higher dialysate glucose exposure. Biases of BTP-estimated GFRs (Shafi-Eqn and Steubl-Eqn) were 1.2 mL/min/1.73 m2 (95% CI 1.0-1.3 mL/min/1.73 m2) and 0.4 mL/min/1.73 m2 (95% CI 0.2-0.6 mL/min/1.73 m2), respectively. Both BTP-estimated GFRs had poor precision (3.2 mL/min/1.73 m2 (95% CI 2.9-3.5 mL/min/1.73 m2) and 2.8 mL/min/1.73 m2 (95% CI 2.5-3.2 mL/min/1.73 m2), respectively) and accuracy of estimates (55% (95% CI 52-60%) and 59% (95% CI 55-63%), respectively). The mean difference of BTP-estimated GFR (Shafi-Eqn and Steubl-Eqn) and measured GFR were -1.14 mL/min/1.73 m2 and -0.42 mL/min/1.73 m2, respectively, with large limit of agreement on Bland-Altman plot. CONCLUSIONS Serum BTP level was inversely related to RKF but neither BTP-estimated GFR equations were sufficiently accurate for routine use in PD patients.
Collapse
Affiliation(s)
- Yong Pey See
- Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.,Australasian Kidney Trial Network, School of Medicine, University of Queensland, Brisbane, QLD, Australia.,Department of Renal Medicine, 63703Tan Tock Seng Hospital, Singapore
| | - Htay Htay
- Department of Renal Medicine, 37581Singapore General Hospital, Singapore
| | - Armando Teixeira-Pinto
- Faculty of Medicine and Health, Sydney School of Public Health, 4334University of Sydney, NSW, Australia
| | - Elaine M Pascoe
- Australasian Kidney Trial Network, School of Medicine, University of Queensland, Brisbane, QLD, Australia
| | - Carmel Hawley
- Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.,Australasian Kidney Trial Network, School of Medicine, University of Queensland, Brisbane, QLD, Australia
| | - Yeoungjee Cho
- Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.,Australasian Kidney Trial Network, School of Medicine, University of Queensland, Brisbane, QLD, Australia
| | - Eileen Zhao
- Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia
| | - David W Johnson
- Department of Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia.,Australasian Kidney Trial Network, School of Medicine, University of Queensland, Brisbane, QLD, Australia
| |
Collapse
|
2
|
Comparison of the new and traditional CKD-EPI GFR estimation equations with urinary inulin clearance: A study of equation performance. Clin Chim Acta 2018; 488:189-195. [PMID: 30445029 DOI: 10.1016/j.cca.2018.11.019] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2018] [Revised: 11/06/2018] [Accepted: 11/12/2018] [Indexed: 01/13/2023]
Abstract
BACKGROUND Diagnosis, prognostication and treatment in chronic kidney disease is often informed by an estimate of the glomerular filtration rate (GFR). Commonly used GFR estimation (eGFR) equations are based on serum creatinine (Cr) concentrations and display suboptimal precision and accuracy. Newer equations incorporating additional endogenous markers such as β-Trace Protein (BTP), β2-Microglobulin (B2M) and cystatin C (cysC) have been developed but require validation. METHODS This prospective cohort study evaluated the performance of 6 eGFR equations developed by the chronic kidney disease - epidemiology collaboration group (CKD-EPI) against urinary inulin clearance GFR in patients recruited from outpatient nephrology clinics. RESULTS Mean biases were negligible and similar between equations. The eGFR-EPI Cr/cysC had the best precision and accuracy of all the equations and the best agreement with inulin mGFR when classifying participants into GFR categories. The BTP and B2M equations displayed the worst precisions and accuracies and showed the least consistent performance across levels of GFR. Thus, the eGFR-EPI Cr/cysC is the least biased, most precise and has the highest accuracy as compared to other eGFR-EPI equations. CONCLUSIONS The BTP and B2M equations are the worst performing of the eGFR-EPI equations, and no benefit is observed with the addition of BTP or B2M to Cr/cysC.
Collapse
|
3
|
Pottel H, Schaeffner E, Ebert N. Evaluating the diagnostic value of rescaled β-trace protein in combination with serum creatinine and serum cystatin C in older adults. Clin Chim Acta 2018; 480:206-213. [PMID: 29476732 DOI: 10.1016/j.cca.2018.02.026] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 02/20/2018] [Accepted: 02/20/2018] [Indexed: 12/27/2022]
Abstract
BACKGROUND Beta trace protein (BTP) is a novel renal biomarker that has emerged as potential alternative or addition to serum creatinine (Scr) and serum cystatin C (ScysC). We analyzed BTP's diagnostic ability to detect impaired kidney function by rescaling it and we tested whether rescaling BTP allowed us to expand the Full-Age-Spectrum (FAS)-equation to BTP. METHODS 566 participants aged ≥70 years with measured glomerular filtration rate (mGFR), Scr, ScysC and BTP from the population-based Berlin Initiative Study (BIS) were considered. We developed a single and combined FAS-equation using rescaled BTP (BTP/0.60) and calculated its sensitivity (S) and specificity (Sp) to identify kidney disease using a fixed (60 mL/min/1.73 m2) and age-dependent threshold for mGFR. RESULTS Rescaled BTP shared the same reference interval with rescaled Scr and ScysC and showed acceptable diagnostic performance (S = 73.1%, Sp = 86.5%), comparable to Scr (S = 71.0%, Sp = 90.5%) and ScysC (S = 80.7%, Sp = 92.9%). Rescaled BTP can be used in the FAS-equation with comparable performance as Scr and ScysC, but the Scr/ScysC/BTP-combined FAS-eq. (P10 = 57.8%, P30 = 96.6%) did not outperform the Scr/ScysC-combined FAS-eq. (P10 = 57.1%, P30 = 96.3%). CONCLUSIONS Rescaled BTP is a valid alternative to Scr or ScysC to diagnose kidney function. The FAS-concept can be applied to BTP or the combination of BTP, Scr and ScysC.
Collapse
Affiliation(s)
- Hans Pottel
- Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium.
| | - Elke Schaeffner
- Charité Universitätsmedizin Berlin, Institute of Public Health, Berlin, Germany
| | - Natalie Ebert
- Charité Universitätsmedizin Berlin, Institute of Public Health, Berlin, Germany
| |
Collapse
|
4
|
Shafi T, Levey AS. Measurement and Estimation of Residual Kidney Function in Patients on Dialysis. Adv Chronic Kidney Dis 2018; 25:93-104. [PMID: 29499893 PMCID: PMC5841591 DOI: 10.1053/j.ackd.2017.09.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 09/11/2017] [Indexed: 12/17/2022]
Abstract
Residual kidney function (RKF) in patients on dialysis is strongly associated with survival and better quality of life. Assessment of kidney function underlies the management of patients with chronic kidney disease before dialysis initiation. However, methods to assess RKF after dialysis initiation are just now being refined. In this review, we discuss the definition of RKF and methods for measurement and estimation of RKF, highlighting the unique aspects of dialysis that impact these assessments.
Collapse
Affiliation(s)
- Tariq Shafi
- Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA.
| | - Andrew S Levey
- Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; and Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, MA
| |
Collapse
|
6
|
Ebert N, Koep C, Schwarz K, Martus P, Mielke N, Bartel J, Kuhlmann M, Gaedeke J, Toelle M, van der Giet M, Schuchardt M, Schaeffner E. Beta Trace Protein does not outperform Creatinine and Cystatin C in estimating Glomerular Filtration Rate in Older Adults. Sci Rep 2017; 7:12656. [PMID: 28978997 PMCID: PMC5627233 DOI: 10.1038/s41598-017-12645-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2017] [Accepted: 09/13/2017] [Indexed: 11/19/2022] Open
Abstract
Despite intense research the optimal endogenous biomarker for glomerular filtration rate (GFR) estimation has not been identified yet. We analyzed if ß-trace protein (BTP) improved GFR estimation in elderly. 566 participants aged 70+ from the population-based Berlin Initiative Study were included in a cross-sectional validation study. BTP, standardized creatinine and cystatin C were measured in participants with iohexol clearance measurement as gold standard method for measured GFR (mGFR). In a double logarithmic linear model prediction of mGFR by BTP was assessed. Analyses with BTP only and combined with creatinine and cystatin C were performed. Additionally, performance of GFR estimating equations was compared to mGFR. We found that the combination of all three biomarkers showed the best prediction of mGFR (r2 = 0.83), whereat the combination of creatinine and cystatin C provided only minimally diverging results (r2 = 0.82). Single usage of BTP showed worst prediction (r2 = 0.67) within models with only one biomarker. Subgroup analyses (arterial hypertension, diabetes, body mass index ≤23 and >30) demonstrated a slight additional benefit of including BTP into the prediction model for diabetic, hypertensive and lean patients. Among BTP-containing GFR equations the Inker BTP-based equation showed superior performance. Especially the use of cystatin C renders the addition of BTP unnecessary.
Collapse
Affiliation(s)
- Natalie Ebert
- Institute of Public Health, Charité University Medicine, Berlin, Germany.
| | - Camilla Koep
- Institute of Public Health, Charité University Medicine, Berlin, Germany
| | - Kristin Schwarz
- Institute of Public Health, Charité University Medicine, Berlin, Germany
| | - Peter Martus
- Institute of Clinical Epidemiology and Medical Biostatistics, Eberhard Karls University, Tübingen, Germany
| | - Nina Mielke
- Institute of Public Health, Charité University Medicine, Berlin, Germany
| | | | - Martin Kuhlmann
- Department of Nephrology, Vivantes Klinikum im Friedrichshain, Berlin, Germany
| | - Jens Gaedeke
- Division of Nephrology, Charité University Medicine, Campus Mitte, Berlin, Germany
| | - Markus Toelle
- Division of Nephrology, Charité University Medicine Campus Benjamin Franklin, Berlin, Germany
| | - Markus van der Giet
- Division of Nephrology, Charité University Medicine Campus Benjamin Franklin, Berlin, Germany
| | - Mirjam Schuchardt
- Division of Nephrology, Charité University Medicine Campus Benjamin Franklin, Berlin, Germany
| | - Elke Schaeffner
- Institute of Public Health, Charité University Medicine, Berlin, Germany
| |
Collapse
|